Immunogenicity, safety, and reactogenicity of heterologous COVID-19 primary vaccination incorporating mRNA, viral-vector, and protein-adjuvant vaccines in the UK (Com-COV2): a single-blind, randomised, phase 2, non-inferiority trial

Stuart ASV., Shaw RH., Liu X., Greenland M., Aley PK., Andrews NJ., Cameron JC., Charlton S., Clutterbuck EA., Collins AM., Darton T., Dinesh T., Duncan CJA., England A., Faust SN., Ferreira DM., Finn A., Goodman AL., Green CA., Hallis B., Heath PT., Hill H., Horsington BM., Lambe T., Lazarus R., Libri V., Lillie PJ., Mujadidi YF., Payne R., Plested EL., Provstgaard-Morys S., Ramasamy MN., Ramsay M., Read RC., Robinson H., Screaton GR., Singh N., Turner DPJ., Turner PJ., Vichos I., White R., Nguyen-Van-Tam JS., Snape MD.

DOI

10.1016/s0140-6736(21)02718-5

Type

Journal article

Publisher

Elsevier BV

Publication Date

2022-01-01T00:00:00+00:00

Volume

399

Pages

36 - 49

Total pages

13

Permalink More information Close